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a  b  s  t  r  a  c  t
Streptococcus agalactiae is a common agent of clinical and subclinical bovine mastitis and
an  important cause of human infections, mainly among pregnant women, neonates and
nonpregnant  adults with underlying diseases. The present study describes the genetic and
phenotypic  diversity among 392 S. agalactiae human and bovine strains isolated between
1980  and 2006 in Brazil. The most prevalent serotypes were Ia, II, III and V and all the
strains  were susceptible to penicillin, vancomycin and levoﬂoxacin. Resistance to clin-
damycin,  chloramphenicol, erythromycin, rifampicin and tetracycline was observed. Among
the  erythromycin resistant strains, mefA/E, ermA and, mainly, ermB gene were detected,
and  a shift of prevalence from the macrolide resistance phenotype to the macrolide-
lincosamide-streptogramin B resistance phenotype over the years was observed. The 23
macrolide-resistant  strains showed 19 different pulsed-ﬁeld gel electrophoresis proﬁles.
Regarding  macrolide resistance, a major concern in S. agalactiae epidemiology, the present
study  describes an increase in erythromycin resistance from the 80s to the 90s followedby  a decrease in the 2000–2006 period. Also, the genetic heterogeneity described points out
that  erythromycin resistance in Brazil is rather due to horizontal gene transmission than to
spreading of speciﬁc macrolide-resistant clones.
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of  severe diseases in newborns and pregnant women, and an
emerging cause of invasive infections in nonpregnant adults,
mostly  in those presenting underlying conditions.3,4
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Asymptomatic colonization can evolve to invasive diseases
in  susceptible human hosts; in animal hosts, non-treated sub-
clinical  mastitis usually turns into chronic cases leading to
permanent  damages.2,4 For this reason, high-quality preven-
tion  and early treatment are crucial goals, which are generally
achieved  through the usage of antimicrobials. In cattle, com-
mercial  solutions (mostly including macrolides, penicillins
and  tetracyclines) are usually employed as one of the mas-
titis  control strategies.2,5 In humans, penicillin remains the
drug  of choice for chemoprophylaxis according to Centers of
Disease  Control (CDC).6
Macrolides and lincosamides represent the alternative in
cases  of therapeutic failure and of patients allergic to beta-
lactams,  although human and bovine GBS strains resistant
to  those drugs have been described in the last decades,
varying from 2.0% to 54.0%.7,8 Likewise, rates of tetracycline-
resistant GBS isolates from human and bovine hosts have been
increasing.8–10
Ten S. agalactiae capsular types were described so far (Ia, Ib,
II–IX),  and serotyping is still the ﬁrst epidemiological approach
to  characterize GBS strains.11 In addition, pulsed-ﬁeld gel
electrophoresis (PFGE) has been used to evaluate the genetic
diversity  and clonal relatedness within this species.8,12,13
In Brazil, few data about the genetic diversity, serotyping
and antimicrobial susceptibility of S. agalactiae are available.
Therefore, here we  provide longitudinal data about distribu-
tion  of capsular types, proﬁles of antimicrobial susceptibility,
including major mechanisms of erythromycin resistance, and
genetic  diversity of erythromycin resistant strains among S.
agalactiae isolated from humans and cattle in Brazil.
Materials  and  methods
Bacterial  strains
A total of 392 GBS strains, including 363 from humans and 29
from  bovine origin, were analyzed. One hundred forty three
strains  were  isolated between 1980 and 1989, 87 between 1990
and  1999 and 162 between 2000 and 2006. Most of the iso-
lates  were  recovered during different studies performed by
our  group, including 289 isolates previously serotyped3,14–16
and were  stored at −20 ◦C in our collection of cultures.
The human originated strains were isolated between 1980
and  2006 in the States of Rio de Janeiro, Santa Catarina, and
São  Paulo, from patients and healthy carriers, including chil-
dren,  pregnant women  and nonpregnant adults, and were
mainly  from throat (n = 69), urine (n = 58), vagina (n = 51), anus
(n  = 22), cervix (n = 18), outer ear (n = 9) and liquor (n = 7). Oth-
ers  less common clinical origins included blood (n = 4), surgical
wounds  (n = 4), peritoneum (n = 1), skin (n = 3), placenta (n = 4),
lungs  (n = 2), sperm (n = 4) and urethra (n = 1). The bovine origi-
nated  strains were  isolated from milk of clinical or subclinical
mastitis cases at 5 different herds in the States of Rio de
Janeiro,  Santa Catarina, and São Paulo, between 1987 and 1989
and  between 2003 and 2006.Determination  of  capsular  serotypes
One hundred and three strains isolated between 2001 and
2002  in Rio de Janeiro from human hosts were serotyped by 1 3;1 7(2):131–136
immunoprecipitation using speciﬁc antisera for types Ia, Ib,
and  II–VIII, which were prepared in house using recognized
reference strains.3
Antimicrobial  susceptibility  testing
Antimicrobial susceptibility testing of 392 strains was per-
formed  by Kirby–Bauer method using clindamycin, chloram-
phenicol, erythromycin, levoﬂoxacin, penicillin, rifampicin,
tetracycline and vancomycin disks (Cecon, São Paulo, Brazil).
Streptococcus pneumoniae ATCC 49619 was used as quality con-
trol  and CLSI breakpoints as the interpretative criteria.17
Determination  of  erythromycin  resistance  phenotypes  and
genotypes
The erythromycin-clindamycin double-disk test was  carried
out  for the determination of the resistance phenotypes
among all the erythromycin resistant strains, as previously
described.18 The presence of ermA, ermB, mefA/E  and lnuB
genes  was  also investigated among these strains using poly-
merase  chain reaction (PCR). DNA extraction was performed
according to Sambrook et al.19 The reactions were  performed
in  a GeneAmp PCR System 2400 (Applied Biosystems) using
primers  and cycles previously described.20–22 PCR-ampliﬁed
products were  run on 1% agarose gels and stained with ethid-
ium  bromide. The 100-bp DNA ladder kit (Invitrogen) was used
as  the DNA size marker.
Pulsed-ﬁeld  gel  electrophoresis  (PFGE)  analysis
PFGE proﬁles from all erythromycin resistant strains were
obtained  as previously described.23 The genomic DNA  was
digested  with the SmaI restriction enzyme (New England Bio-
labs,  Ipswich, MA, USA) and electrophoresis was  performed
in  a CHEF DR III system (Bio-Rad Laboratories, USA) using the
following  program:  switch time 1–30 s during 23 h with a 120◦
angle at a temperature of 11.3 ◦C and a voltage gradient of
6  V/cm. The Lambda Ladder PFG marker kit (New England Bio-
labs,  USA) was used as the DNA size marker. The gels were
stained  with ethidium bromide and digitally photographed
using a Scorpion SCOR-14SOM scanner (DNR Bioimaging Sys-
tem,  Jerusalém, Israel) under ultraviolet light. The images were
analyzed  using Gel ComparII® software (Applied Maths, Bel-
gium).  Electrophoretic proﬁles were  compared according to
the  guidelines proposed by Tenover et al.24 The Dice coefﬁcient
(95%)  and a 1% position tolerance were used to analyze the
similarities  in the band patterns among the electrophoretic
proﬁles. The unweighted pair group method using the arith-
metic  average was  used to gather electrophoretic proﬁles
into  polymorphism patterns, also referred to as clusters. The
polymorphism patterns were deﬁned grouping proﬁles that
showed  >70% dendrogram identity.
ResultsAnalyzing our serotyping data together with data previ-
ously  described,3,16,25 the strains were  classiﬁed as follows:
Ia  = 23.5% (92 strains), Ib = 5.3% (21), II = 15.0% (59), III = 18.9%
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Fig. 1 – Distribution of serological types among S. agalactiae strains from human and bovine origins according to the period
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74), IV = 2.8% (11) and V = 14.8% (58). Serotype III prevailed
mong the human strains and type V among the bovine ones.
eventy-seven strains (19.7%) were non-typeable. Fig. 1 shows
he  distribution of serotypes along time.
All the bovine and human isolates were susceptible to peni-
illin,  vancomycin and levoﬂoxacin. However, resistance to
lindamycin  (20.7% and 1.9% in bovine and human strains,
espectively), erythromycin (27.6 and 4% in bovine and human
trains,  respectively), and tetracycline (89.6 and 89.2% in
ovine  and human strains, respectively) was  detected among
trains  from both origins. Resistance to chloramphenicol
nd rifampicin was  detected only among human originated
trains, with rates of 1.5% and 0.7% respectively. All the
rythromycin-resistant GBS strains from human origin were
solated  from carriers or cases of noninvasive infections. All
he  clindamycin-resistant strains were also resistant to eryth-
omycin.  The distribution of resistant strains according to
rigin  (bovine or human) and along time is shown in Fig. 2.
Constitutive  macrolide-lincosamide-streptogramin B
cMLSB) and macrolide (M)  phenotypes were equally dis-
ributed  among the 23 erythromycin-resistant isolates, with
2  and 11 strains each one respectively, although the ﬁrst
revailed  among the bovine (75.0%) and the second among
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Fig. 2 – Distribution of S. agalactiae resistant strains acthe  human (60.0%) erythromycin-resistant GBS isolates. The
inducible  MLSB phenotype was not observed. The ermB gene
was  the most common resistance determinant in both human
and  bovine erythromycin-resistant isolates, while lnuB gene
was  not detected. Fourteen erythromycin-resistant strains
analyzed  (60.8%) had 2 or 3 erythromycin resistance determi-
nants,  and the combination ermB/mefA/E was  predominantly
found in 26.1% (6 strains). Only one S. agalactiae strain, isolated
from  a human host, did not harbor any of the erythromycin
resistance genes tested. All M phenotype strains harbored the
mefA/E  gene, either alone or in combination with an erm (A
or  B) gene, while all the cMLSB phenotype strains had an erm
gene,  either alone or in combination with the mefA/E  gene.
PFGE  revealed a high heterogeneous population, as shown
in  Fig. 3, with 19 distinct electrophoretic proﬁles distributed
among the 23 erythromycin-resistant GBS strains analyzed,
suggesting a polyclonal origin for erythromycin resistance
in  our region. Four major clusters were observed, and the
predominant one (cluster A) harbored 7 strains from both
human  and bovine origins. Similar genetic proﬁles were
observed in different States of Brazil, as well as among
strains belonging to different serotypes. In addition, one
human  originated serotype III strain from Rio de Janeiro and
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Fig. 3 – Genetic diversity and phenotypic characterization of S. agalactiae macrolide-resistant strains. Pulsed-ﬁeld gel
electrophoresis (PFGE) proﬁles, strain identiﬁcation numbers, years of isolation, origins, serotypes, resistance phenotypes
and resistance genes. cMLSB: constitutive macrolides, lincosamides and streptogramins B-type resistance; M,  macrolides
resistance; NT, non-typeable.
one bovine serotype II strain from São Paulo had identical
proﬁles.
Discussion
In United States, Europe and Australia serotypes Ia, II, III and
V  account for 80–90% of the isolated strains, while serotypes
IV,  VI, VII, VIII and IX remain rarely described.11,12,26,27 In
the present study serotypes Ia, II, III and V were collectively
detected in approximately 70% of the strains. This ﬁnding is
consistent  with previously reported data. Around 20% of our
strains  were  non-typeable and similar data were described
recently in our region.23 On the other hand, lower rates, vary-
ing  between 4 and 15%, have been reported by others.8,28 The
use  of molecular techniques to detect the capsular gene in the
latter  may  explain this discrepancy.
Susceptibility to vancomycin, penicillin and levoﬂoxacin
and a high level of resistance to tetracycline (89%) were
observed in the present study. These data were also described
previously in other countries13,29 and in Brazil.15,23,30,31
Although strains resistant to penicillin and levoﬂoxacin have
been  described, they remain as exceptions.32,33
The tetracycline resistance rates can reach or overcome the
90%  index. Tetracycline resistance rates observed among GBS
isolates  from humans agree with previous local and global
studies.9,23,32 However, the rate among GBS from cattle is con-
siderably higher than previous data, which had revealed only
44.7%  and 14.5% of tetracycline resistance in Brazil30 and inthe  United States,9 respectively. The rise of tetracycline resis-
tance  is of concern since it is one of the main antimicrobials
used in mastitis control.2,5 Moreover, according to our results,
the  general rate of tetracycline resistance (including strains
from  human and bovine origins) has increased from 86% to
91%  from 80s to 90s and has been constantly high since then.
Although  the rate of erythromycin resistance among S.
agalactiae  from human hosts analyzed in the present study
has  increased from the 80s to the 90s but decreased by
2006,  it is still important to track erythromycin resistance
among Brazilian S. agalactiae strains. Recently, rates around
13%  and 11%, which would rule out this drug as an alter-
native option, have been described in Rio de Janeiro.23,33
Among strains from bovine origin, resistance to erythro-
mycin increased from 10.5% in 1987 and 1988 to 60% in
2003  and 2006. This is probably also due to the proximity
among the collection herds investigated in 2006; hereafter
mentioned.
Prevalence of cMLSb phenotype increased along the years,
while  prevalence of M phenotype decreased. The predomi-
nance  of MLSb phenotype among S. agalactiae strains obtained
in  the last ten years was reported in Brazil and in other
countries.23,33–35 The predominant resistance genotype was
ermB+  mefA/E+, suggesting that the majority of our strains
have  both resistance mechanisms, efﬂux and ribosomal mod-
iﬁcation.  The three states included in the study (Rio de Janeiro,
Santa  Catarina, and São Paulo) were  represented among the
23  erythromycin-resistant GBS, and no correlation between
erythromycin resistance and a speciﬁc serotype was observed,
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ince resistant strains belonged to a variety of them (Ia, II, III,
V  and V, and NT).
The  increasing resistance to macrolides among group B
treptococci has been observed during recent years in many
ountries.  It is particularly important from the epidemiolog-
cal  point of view to perform speciﬁc characterization of S.
galactiae  isolates, focused on, among others, answering if the
henomenon  occurred due to the spread of a speciﬁc S. agalac-
iae  clone in the population or if it is the result of acquired
esistance or both. Some authors have associated macrolide
esistance to the introduction of speciﬁc S. agalactiae clones,
ncluding  mostly serotype V strains.28,34,36 The present study,
owever, did not show association between speciﬁc S. agalac-
iae  clones or serotypes and the macrolide resistance proﬁle
mong  strains from human origin, indicating that horizon-
al  genetic transfer is the main force behind the appearance
f  erythromycin resistance in our region. Similar data were
escribed  previously for S. agalactiae strains isolated in 2008 in
io de Janeiro.23 Indeed, some authors have shown that eryth-
omycin  resistance determinants are carried by conjugative
ransposons, which are easily self-transferable and commonly
ound  among S. agalactiae strains.37,38
Regarding the bovine strains, however, it is important to
ighlight  the serotype V cluster (cluster C) observed in 2006.
hese  isolates were recovered from herds in the South Cen-
ral  region of Rio de Janeiro and, although more  studies are
ecessary  to evaluate this hypothesis, it seems that they rep-
esent  a successful clone, well-adapted to the local cattle, and
issemination  to the metropolitan region, which is nearby,
ould  easily happen. Moreover, the ﬁnding of a major clus-
er,  cluster A, comprising human and bovine originated GBS
trains  suggests that, although erythromycin resistance is
ather  emerging due to horizontal genetic transfer, success-
ul  clones, which can be found among strains from humans
nd  cattle, have the ability to capture and exchange this kind
f  mobile genetic elements.
A  GBS strain from human origin, isolated in Rio de Janeiro
n  1981, and one from cattle, isolated in São Paulo in 1987,
howed indistinguishable electrophoretic proﬁles (cluster E).
he genetic relationship between bovine and human origi-
ated  strains has been for a long time speculated and previous
tudies  around the world have, as well, demonstrated very
imilar  or identical genotypes among them.39–41 In fact, we
urselves have earlier reported human and bovine GBS strains
haring  genetic (same PFGE proﬁle, ribotype and related ST)
nd  phenotypic (in vivo virulence proﬁle) characteristics, indi-
ating  a common evolutionary origin and suggesting that
trains  from different hosts could presumably transfer genetic
aterial  between each other.25,42 Nevertheless, there is still a
ot  to elucidate about this hypothesis.
onclusion
n the present study, almost four hundred S. agalactiae human
nd  bovine strains collected during a 27-year period were
haracterized by phenotypic and genetic aspects, generating
riginal and valuable data on serological typing, antimicro-
ial  susceptibility proﬁle and genetic diversity, in order to help
lucidating  GBS epidemiology in Brazil. Furthermore, our data
13;1  7(2):131–136  135
about  macrolide resistant strains, a major concern regarding
the  epidemiology of S. agalactiae, point out that it is rather due
to  horizontal gene transfer than to monoclonal dissemination
among Brazilian strains.
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